Sunrise is a leading researcher and developer of solutions for diagnosis and treatment of sleep apnea. Our goal is to develop and commercialise EIisa, the first truly non-invasive, affordable and readily accessible solution to treat sleep apnea. This is to address the 80% treatment gap of sleep apnea sufferers who fail to access treatment due to high costs and long waiting times for diagnosis. Also, even within those diagnosed, at least 35% fail to comply with wearing a mask all night strapped tightly to the face, blowing air to clear airways for breathing due to the associated discomfort. In contrast EIisa is a wearable device involving no nasal obstruction, which uses mild electric muscle stimulation to train jaw muscles for preventing airways from collapsing during sleep. EIisa is set to improve treatment access, compliance, cost and accuracy. We anticipate to reach €129.4Mn in cumulative revenue by 2028 and employ over 150 people.
- Invested amount